[go: up one dir, main page]

UA97392C2 - 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин как соединение с комбинированной активностью в отношении обратного захвата серотонина, 5-нт3 и 5-нт1a для лечения боли - Google Patents

1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин как соединение с комбинированной активностью в отношении обратного захвата серотонина, 5-нт3 и 5-нт1a для лечения боли

Info

Publication number
UA97392C2
UA97392C2 UAA200910355A UAA200910355A UA97392C2 UA 97392 C2 UA97392 C2 UA 97392C2 UA A200910355 A UAA200910355 A UA A200910355A UA A200910355 A UAA200910355 A UA A200910355A UA 97392 C2 UA97392 C2 UA 97392C2
Authority
UA
Ukraine
Prior art keywords
piperazine
pain
phenyl
treatment
dimethylphenylsulfanyl
Prior art date
Application number
UAA200910355A
Other languages
English (en)
Ukrainian (uk)
Inventor
Николас Мур
Тине Брайан Стенсбьол
Original Assignee
Х. Луннбэк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39564604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA97392(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Х. Луннбэк А/С filed Critical Х. Луннбэк А/С
Publication of UA97392C2 publication Critical patent/UA97392C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение касается применения 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина и его фармацевтически приемлемых кислотно-аддитивных солей (соединение I) для производства лекарственного средства для лечения боли.
UAA200910355A 2007-03-20 2008-03-14 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин как соединение с комбинированной активностью в отношении обратного захвата серотонина, 5-нт3 и 5-нт1a для лечения боли UA97392C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700427 2007-03-20
PCT/DK2008/050063 WO2008113359A2 (en) 2007-03-20 2008-03-14 1- [2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition

Publications (1)

Publication Number Publication Date
UA97392C2 true UA97392C2 (ru) 2012-02-10

Family

ID=39564604

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200910355A UA97392C2 (ru) 2007-03-20 2008-03-14 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин как соединение с комбинированной активностью в отношении обратного захвата серотонина, 5-нт3 и 5-нт1a для лечения боли

Country Status (29)

Country Link
US (1) US8664225B2 (ru)
EP (1) EP2142193B1 (ru)
JP (1) JP5371790B2 (ru)
KR (1) KR101459168B1 (ru)
CN (2) CN103948597A (ru)
AR (1) AR065797A1 (ru)
AT (1) ATE495745T1 (ru)
AU (1) AU2008228638B2 (ru)
BR (1) BRPI0808941A2 (ru)
CA (1) CA2684571C (ru)
CL (1) CL2008000795A1 (ru)
CO (1) CO6220962A2 (ru)
CY (1) CY1111183T1 (ru)
DE (1) DE602008004643D1 (ru)
DK (1) DK2142193T3 (ru)
EA (1) EA017058B1 (ru)
ES (1) ES2355434T3 (ru)
HR (1) HRP20110058T1 (ru)
IL (2) IL200956A (ru)
MX (1) MX2009009672A (ru)
MY (1) MY150448A (ru)
NZ (1) NZ579721A (ru)
PL (1) PL2142193T3 (ru)
PT (1) PT2142193E (ru)
RS (1) RS51560B (ru)
SI (1) SI2142193T1 (ru)
TW (1) TW200848411A (ru)
UA (1) UA97392C2 (ru)
WO (1) WO2008113359A2 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2439201B1 (en) * 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
US8940746B2 (en) * 2009-04-24 2015-01-27 H. Lundbeck A/S Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine
SG178325A1 (en) 2009-08-24 2012-03-29 Lundbeck & Co As H New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
CA2797812C (en) * 2010-04-30 2018-02-20 Takeda Pharmaceutical Company Limited Enteric tablet
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
CA2885266C (en) * 2012-09-19 2020-05-12 Sandoz Ag Novel crystalline form of vortioxetine hydrobromide
US20160200698A1 (en) * 2013-09-12 2016-07-14 Hangzhou Pushai Pharmaceutical Technology Co., Ltd Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
KR20160093025A (ko) 2013-12-20 2016-08-05 하. 룬트벡 아크티에 셀스카브 멜랑코리성 특색을 갖는 우울 장애의 치료를 위한 카파-활성을 갖는 오피오이드 수용체 길항제 및 보티옥세틴의 용도
WO2015114395A1 (en) 2014-01-31 2015-08-06 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
CN104059030B (zh) 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN105198837B (zh) * 2014-06-09 2018-05-04 上海医药工业研究院 一种沃替西汀氢溴酸盐晶体及其制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN106279066A (zh) * 2015-05-22 2017-01-04 天津药物研究院有限公司 一种氢溴酸沃替西汀晶体的纯化方法
CN106556663B (zh) * 2015-09-30 2018-05-29 成都弘达药业有限公司 一种1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪或其盐的检测方法
US10927089B2 (en) 2016-06-16 2021-02-23 Sunshine Lake Pharma Co., Ltd. Diaryl thioether piperazine compounds, preparation methods and uses thereof
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
US11124491B2 (en) * 2017-04-25 2021-09-21 H. Lundbeck A/S Process for the manufacture of vortioxetine HBr alpha-form
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
UA81749C2 (ru) * 2001-10-04 2008-02-11 Х. Луннбек А/С производные фенилпиперазина как ингибиторы обратного захвата серотонинА
CA2467118A1 (en) * 2001-12-20 2003-07-03 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
EP2439201B1 (en) * 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity

Also Published As

Publication number Publication date
CA2684571C (en) 2012-08-14
IL238068A0 (en) 2015-05-31
IL200956A0 (en) 2010-05-17
HRP20110058T1 (hr) 2011-03-31
PL2142193T3 (pl) 2011-04-29
BRPI0808941A2 (pt) 2014-08-19
CY1111183T1 (el) 2015-06-11
WO2008113359A2 (en) 2008-09-25
DK2142193T3 (da) 2011-03-28
JP5371790B2 (ja) 2013-12-18
KR20090125251A (ko) 2009-12-04
EP2142193B1 (en) 2011-01-19
CO6220962A2 (es) 2010-11-19
TW200848411A (en) 2008-12-16
NZ579721A (en) 2011-07-29
CL2008000795A1 (es) 2008-09-26
KR101459168B1 (ko) 2014-11-07
AU2008228638A1 (en) 2008-09-25
WO2008113359A3 (en) 2008-11-13
AR065797A1 (es) 2009-07-01
DE602008004643D1 (de) 2011-03-03
EP2142193A2 (en) 2010-01-13
RS51560B (sr) 2011-06-30
US20110009422A1 (en) 2011-01-13
ES2355434T3 (es) 2011-03-25
MX2009009672A (es) 2009-12-15
CN101636161A (zh) 2010-01-27
CN103948597A (zh) 2014-07-30
PT2142193E (pt) 2011-02-02
JP2010521501A (ja) 2010-06-24
IL200956A (en) 2015-05-31
EA017058B1 (ru) 2012-09-28
SI2142193T1 (sl) 2011-03-31
ATE495745T1 (de) 2011-02-15
MY150448A (en) 2014-01-30
US8664225B2 (en) 2014-03-04
AU2008228638B2 (en) 2012-09-20
CA2684571A1 (en) 2008-09-25
EA200970870A1 (ru) 2010-04-30

Similar Documents

Publication Publication Date Title
UA97392C2 (ru) 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин как соединение с комбинированной активностью в отношении обратного захвата серотонина, 5-нт3 и 5-нт1a для лечения боли
TNSN08460A1 (en) 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
MX2010004688A (es) Usos terapeuticos de compuestos que tienen actividad combinada de sert, 5- ht3 y 5-ht1a.
MY163537A (en) 4- [2- (4-methylphenylsulfanyl)phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression
NI201000093A (es) Toalla para llevar puesta
MX2011011119A (es) Formulaciones liquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil) fenil] piperazina.
EP2220074A4 (en) 3,5-SUBSTITUTED INDOL COMPOUNDS WITH NOS AND NOREPINEPHRINE RECOVERY-HEMDERING EFFECT
PT2398785E (pt) Purificação de 1-[2-(2,4-dimetil-fenilsulfonil) fenil]piperazina
SMT201300108B (it) Nuove composizioni di 1-Ä2-(2,4-dimetilfenil solfanil)-fenilÜ piperazina
MX349724B (es) Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperaz ina.
NZ604883A (en) Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals
NZ601735A (en) Antibody with binding specificity for Nedd4 protein for reducing influenza infectivity
TW200631952A (en) Benzdioxan piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
AU2016202490A1 (en) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
UA95801C2 (ru) Кристаллические формы 4-[2-(4-метилфенилсульфанил)-фенил]пиперидина с комбинированным ингибированием обратного захвата серотонина и норэпинефрина для лечения невропатической боли
UA101341C2 (ru) Терапевтические применения соединений, которые имеют комбинированную активность в отношении sert, 5-нт3 и 5-нт1a
UA101005C2 (ru) 4-[2-(4-метилфенилсульфанил)фенил]пиперидин для лечения депрессии совместно с синдромом раздраженного кишечника (ibs)
HK1145494A (en) 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity